Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 4/2000

01-04-2000 | Adis Drug Evaluation

Prolonged-Release Mesalazine

A Review of its Therapeutic Potential in Ulcerative Colitis and Crohn’s Disease

Authors: Delyth Clemett, Anthony Markham

Published in: Drugs | Issue 4/2000

Login to get access

Summary

Abstract

Prolonged-release mesalazine (Pentasa®2) consists of ethylcellulose-coated microgranules from which mesalazine (known in the US as mesalamine) is released in the small and large intestine in a diffusion-dependent manner.
Dose-dependent improvements in clinical and endoscopic parameters have been reported with prolonged-release mesalazine 2 and 4 g/day in clinical trials in patients with mild to moderately active ulcerative colitis. Induction of clinical and endoscopic remission was achieved in more patients receiving a daily dosage of 4 g/day than in those receiving placebo.
In patients with ulcerative colitis in remission, prolonged-release mesalazine is effective in reducing the rate of relapse. Higher dosages tend to be more effective, and a 12-month remission rate of 64% has been reported for patients treated with a 4g daily dosage of this formulation. Comparative data indicate that prolonged-release mesalazine has similar efficacy in maintaining remission to molar equivalent doses of sulfasalazine.
Data from a study in patients with mild to moderately active Crohn’s disease indicates that higher dosages (4 g/day) of prolonged-release mesalazine are more effective than placebo in reducing disease activity. After 16 weeks’ treatment, 64% of patients receiving a 4 g/day dosage experienced clinical improvement and 43% attained remission. In studies of patients in remission of Crohn’s disease, the formulation appears to be more effective in preventing relapse in patients with isolated small bowel disease than in those with colonie involvement.
The tolerability profile of oral prolonged-release mesalazine is similar to that of placebo and the incidence of adverse events does not appear to be dose-related. Nausea/vomiting, diarrhoea, abdominal pain and dyspepsia occur most frequently, although their incidence is low. Reports of nephrotoxicity during prolonged-release mesalazine treatment are rare.
Conclusions: Oral prolonged-release mesalazine is effective for maintenance and induction of remission of mild to moderately active colitis, both in patients with distal disease and in those with pancolitis. The formulation has similar efficacy to that of equimolar concentrations of sulfasalazine. Prolonged-release mesalazine also appears to be effective in the treatment of Crohn’s disease, and maintenance therapy is of particular value in patients with isolated small bowel involvement. Evidence suggests that higher dosages (3 to 4 g/day) of prolonged-release mesalazine have additional therapeutic benefits over lower dosages in patients with inflammatory bowel disease without increasing the incidence of adverse events.

Mode of Action

The mechanism by which mesalazine exerts its therapeutic actions remains elusive. However, numerous in vitro studies have indicated modulatory actions of mesalazine on the lipid mediators, cytokines and reactive oxygen species involved in the nonspecific inflammation and tissue damage characteristic of ulcerative colitis and Crohn’s disease.
In vitro studies have consistently demonstrated inhibitory effects of mesalazine on leukotriene (LT)B4 synthesis and release from biopsy specimens from individuals with normal colons and from patients with inflammatory bowel disease. Although mesalazine had conflicting effects on prostaglandin (PG)E2 levels, higher concentrations appeared to considerably reduce PGE2 production in colonic mucosa from patients with ulcerative colitis. Mesalazine also appears to reduce in vitro levels of LTC4, 5-hydroxyeicosatetraenoic acid (HETE), 11-, 12-, 15-HETE, PGD2 and platelet-activating factor.
In addition to inhibiting interferon (IFN)-γbinding, mesalazine reduced IFNγ-induced cell permeability and expression of the HLA-DR product of the major histocompatibility complex in colonic epithelial cell lines. Recent evidence suggests that mesalazine reverses the antiproliferative effects of tumour necrosis factor-(TNF)α and inhibits TNFα signalling events in intestinal cells. Mesalazine may also reduce interleukin (IL)-1/1β and IL-2 production.
Mesalazine reduced production of reactive oxygen species and protected against oxidant-induced tissue injury in several in vitro models.

Pharmacokinetic Properties

Entry of water into prolonged-release mesalazine microgranules creates a concentration gradient down which mesalazine diffuses, liberating active drug throughout the small bowel and colon.
Prolonged-release mesalazine acts topically in the affected bowel lumen. In volunteers, 18 to 20% of the administered dose was delivered to the jejunoileal segment as solubilised drug, while cumulative colonic delivery was 82% (approximately 75% as intact microgranules) during the first 7 hours after drug administration. Food intake, local pH and diarrhoeal states do not appear to substantially affect the disposition of mesalazine from the prolonged-release formulation.
Mesalazine is primarily metabolised by acetylation in the gut wall and liver, forming acetyl mesalazine. After oral administration, up to 53% of the administered dose is excreted in the urine as mesalazine plus acetyl mesalazine. Faecal excretion accounts for 40% of the administered dose (14 to 19% as unchanged mesalazine, although exact levels of acetylated and nonacetylated mesalazine in different colonie segments are not known).

Therapeutic Efficacy

Prolonged-release mesalazine at dosages up to 4 g/day has been investigated for the maintenance of remission and treatment of mild to moderately active ulcerative colitis and Crohn’s disease. Higher doses of prolonged-release mesalazine (3 to 4 g/day) were generally more effective than low doses (1.5 to 2 g/day) for treatment of acute exacerbations and for maintenance of disease remission.
At dosages of 2 or 4 g/day, the formulation improved clinical and endoscopic findings in patients with active ulcerative colitis, and success of treatment was independent of disease location. At a dosage of 1.5 g/day, the prolonged-release formulation was as effective as sulfasalazine 3 g/day in improving clinical and endoscopic parameters.
The estimated 1-year remission rate in patients with quiescent ulcerative colitis receiving prolonged-release mesalazine 1.5 g/day was similar to that with sulfasalazine 3 g/day (54 vs 46%). A 4g daily dosage of the mesalazine formulation was more effective than placebo in preventing endoscopie and clinical relapse (1-year remission rates 64 vs 38%).
Low dosages (≤2 g/day) of prolonged-release mesalazine had no significant benefits over placebo in patients with mild to moderately active Crohn’s disease. However, the formulation showed benefits compared with placebo at a dosage of 4 g/day in 1 study. In another study, prolonged-release mesalazine 4 g/day produced improvement, but was not statistically better than placebo. In addition to increasing the percentage of patients in remission, or experiencing therapeutic benefit, prolonged-release mesalazine reduced the time to remission and the percentage of treatment failures, compared with placebo. In another study, 16-week remission rates were significantly higher in patients receiving oral budesonide 9 mg/day than in those treated with a4g daily dosage of prolonged-release mesalazine (62 vs 36%).
During prolonged-release mesalazine treatment for maintenance of remission of Crohn’s disease, dosages of ≤2 g/day were not consistently effective in producing benefits over placebo. However, significantly lower relapse rates were reported in patients treated with a 3g daily dosage than in those receiving placebo over a 48-week period. In a noncomparative study of up to 30 months’ duration, dosages of ≤4 g/day (median 3.7 g/day) were effective in maintaining 72% of patients continuously in remission over a 1-year period. Prolonged-release mesalazine showed particular benefit in reducing the rate of relapse in patients with isolated ileal disease. Endoscopie recurrence rates after 1 year in patients with a recent surgical resection of the affected bowel were significantly lower in those receiving prolonged-release mesalazine 3 g/day than in placebo recipients.
Improvements in disease status have been reported in children (aged 9 to 18 years) receiving prolonged-release mesalazine (22 to 53 mg/kg/day) for the treatment of active Crohn’s disease.

Tolerability

There is no evidence of a dose relationship in the adverse events profile of prolonged-release mesalazine and the tolerability profile is similar to that of placebo. The most common adverse events considered related to treatment with the mesalazine formulation at dosages up to 4 g/day were nausea and/or vomiting, headache, abdominal pain, diarrhoea and dyspepsia. Treatment-related adverse events necessitating study withdrawal occurred less commonly in patients receiving a 4g daily dosage of prolonged-release mesalazine than in those receiving placebo.
Although nephrotoxicity has been associated with the use of other mesalazine-containing preparations, impaired renal function does not appear to be associated with use of the prolonged-release formulation. However, as with other mesalazine preparations, precautionary monitoring of serum creatinine levels has been advocated.
Prolonged-release mesalazine appears to be well tolerated in patients intolerant of sulfasalazine. In patients who had experienced infertility as a result of sulfasalazine treatment, sperm quality was improved or normalised after switching to prolonged-release mesalazine treatment.

Dosage and Administration

Oral prolonged-release mesalazine at dosages up to 4 g/day is indicated for the induction of remission and treatment of mild to moderate ulcerative colitis in adults. For patients with quiescent disease, the recommended starting dosage is 1.5 g/day in 2 or 3 divided doses. However, evidence from clinical trials of dosages up to 4 g/day indicates a dose-dependent increase in efficacy.
No US or UK dosage recommendations are available for the use of prolonged-release mesalazine in the management of Crohn’s disease. However, individualised dosage of up to 4 g/day in divided doses is generally recommended for the treatment of active disease and maintenance of remission in other countries.
Prolonged-release mesalazine should not be used in patients with known sensitivity to salicylates or in those with severe renal and/or liver impairment, and is not recommended for use in children. The formulation should be used with caution during pregnancy.
Literature
1.
Martin F. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease: an update. Dig Dis Sci 1987; 32 (12 Suppl.):57S–63SPubMed
2.
Azad Khan AK, Piris J, Truelove SC. An experiment ot determine the active therapeutic moiety of sulphasalazine. Lancet 1979; II(8044): 892–5
3.
Schröder H, Price E, Evans DA. Acetylator phenotype and adverse events of sulphasalazine in healthy subjects. Gut 1972; 13(4): 278–84PubMed
4.
Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16(6): 738–40PubMed
5.
Geier DL, Miner Jr PB. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992; 93: 199–208PubMed
6.
Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 1993; 33: 712–8PubMed
7.
Järnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994; 35: 1155–8PubMed
8.
Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841–8PubMed
9.
Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990; 78: 119–25PubMed
10.
Greenfield SM, Punchard NA, Teare JP, et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369–83PubMed
11.
Travis SPL, Jewell DP. Salicylates for ulcerative colitis — their mode of action. Pharmacol Ther 1994; 63: 135–61PubMed
12.
Schmidt C, Fels T, Baumeister B, et al. The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells. Curr Med Res Opin 1996; 13(7): 417–25PubMed
13.
Capasso F, Tavares IA, Bennett A. Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid. Drugs Exp Clin Res 1991; 17: 351–3PubMed
14.
Rachmilewitz D, Karmeli F, Schwartz LW, et al. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 929–32PubMed
15.
Di Paolo MC, Merrett MN, Crotty B, et al. 5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Gut 1996; 38: 115–9PubMed
16.
Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991; 36: 174–8PubMed
17.
Sandoval M, Liu X, Mannick EE, et al. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 1997; 113: 1480–8PubMed
18.
Horn H, Preclik G, Stange EF, et al. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand J Gastroenterol 1991; 26: 867–79PubMed
19.
Gertner DJ, Rampton DS, de Nucci G, et al. Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: effects of conventional and potential new therapies. Eur J Gastroenterol Hepatol 1992; 4: 837–41
20.
Eliakim R, Karmeli F, Chorev M, et al. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol 1992; 27: 968–72PubMed
21.
Fox C, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991; 36: 179–84PubMed
22.
Rachmilewitz D, Karmeli F, Eliakim R. Platelet-activating factor — a possible mediator in the pathogenesis of ulcerative colitis. Scand J Gastroenterol 1990; 25 Suppl. 172: 19–21
23.
Bruin KF, Hommes DW, Jansen J, et al. Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 791–5PubMed
24.
Mahida YR, Lamming CED, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 β production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50–4PubMed
25.
Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272: 399–406PubMed
26.
Mazlam MZ, Montazeri G, Hodgson HJF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro. Eur J Gastroenterol Hepatol 1993; 5: 515–20
27.
Dallegri F, Ottonello L, Ballestrero A, et al. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990; 31: 184–6PubMed
28.
Lobos EA, Sharon P, Stenson WF. Chemotactic activity in inflammatory bowel disease: role of leukotriene B4. Dig Dis Sci 1987; 32(12): 1380–8PubMed
29.
Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86(3): 453–60PubMed
30.
Lauritsen K, Laursen LS, Bukhave K, et al. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91(4): 837–44PubMed
31.
Guimbaud R, Izzo A, Martinolle JP, et al. Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Dig Dis Sci 1995; 40(12): 2635–40PubMed
32.
Eliakim R, Kanneli F, Razin E, et al. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine and prednisolone. Gastroenterology 1988; 95(5): 1167–72
33.
Thyssen E, Turk J, Bohrer A, et al. Quantification of distinct molecular species of platelet-activating factor in ulcerative colitis. Lipids 1996; 31 Suppl.: S255–9PubMed
34.
Sobhani I, Hochlaf S, Denziot Y, et al. Raised concentrations of platelet activating factor in colonic mucosa of Crohn’s disease patients. Gut 1992; 33(9): 1220–5PubMed
35.
Crotty B, Hoang P, Dalton HR, et al. Salicylates used in inflammatory bowel disease and colchicine impair interferon-γ induced HLA-DR expression. Gut 1992; 33: 59–64PubMed
36.
Crotty B, Rosenberg WMC, Aronson JK, et al. Inhibition of binding of interferon-γ to its receptor by salicylates used in inflammatory bowel disease. Gut 1992; 33: 1353–7PubMed
37.
Horie Y, Chiba M, Suzuki T, et al. Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. J Gastroenterol 1998; 33(1): 39–47PubMed
38.
Selby WS, Janossy G, Mason DY, et al. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 1983; 53(3): 614–8PubMed
39.
McDonald GB, Jewell DP. Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon. J Clin Pathol 1987; 40: 312–7PubMed
40.
Ishii N, Chiba M, Iiziuka M, et al. Induction of HLA-DR antigen expression on human colonic epithelium by tumor necrosis factor-α and interferon-γ. Scand J Gastroenterol 1994; 29(10): 903–7PubMed
41.
Oberhuber G, Püspök A, Peck-Radosavlevic M, et al. Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn’s disease. Am J Surg Pathol 1999; 23(8): 970–6PubMed
42.
Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κ-B activation in mouse colonocytes. Gastroenterology 1999; 116: 602–9PubMed
43.
Greenfield SM, Hamblin AS, Shakoor ZS, et al. Inhibition of leucocyte adhesion molecule upregulation by tumour necrosis factor a: a novel mechanism of action of sulphasalazine. Gut 1993; 34: 252–6PubMed
44.
Simmonds AJ, Allen RE, Stevens TRJ, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992; 103(1): 186–96PubMed
45.
Keshavarzian A, Sedghi S, Kanofsky J, et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1002; 103(1): 177–85
46.
Prónai L, Yukinobu I, Lang I, et al. The oxygen-centered radicals scavenging activity of sulphasalazine and its metabolites. A direct protection of the bowel. Acta Physiol Hung 1992; 80: 317–23
47.
Greenfield SM, Punchard NA, Thompson RPH. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid. Gut 1991; 32: 1156–9PubMed
48.
Simmonds NJ, Millar AD, Blake DR, et al. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999; 13: 363–72PubMed
49.
Yu DK, Morrill B, Eichmeier LS, et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur J Clin Pharmacol 1995; 48: 273–7PubMed
50.
Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 2000; 14: 163–9PubMed
51.
Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy 1994; 14: 385–98PubMed
52.
Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-Aminosalicylic acid in a slow-release prepararation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982; 83: 1062–70PubMed
53.
Stolk LM, Rietbroek R, Wiltink EH, et al. Dissolution profiles of mesalazine formulations in vitro. Pharm Weekbl Sci 1990; 12: 200–4PubMed
54.
Larouche J, Morais J, Picard M, et al. Release of 5-ASA from Pentasa in patients with Crohn’s disease of the small intestine. Aliment Pharmacol Ther 1995; 9: 315–20PubMed
55.
Wilding IR. A scintigraphic study to evaluate what happens to Pentasa® and Asacol® in the human gut. Pract Gastroenterol 1999: 1–8
56.
Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 1427–33PubMed
57.
Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-amino-salicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 523–33PubMed
58.
Christensen LA, Fallingborg J, Jacobsen B A, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994; 8: 289–94PubMed
59.
Christensen LA, Slot O, Sanchez G, et al. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol 1987; 23: 365–9PubMed
60.
Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol 1992; 27: 863–8PubMed
61.
Bondesen S, Tage-Jensen U, Jacobsen O, et al. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. Eur J Clin Pharmacol 1986; 31: 23–6
62.
Bondesen S, Hegnhoj J, Larsen F, et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and Per Os slow-release formulation. Dig Dis Sci 1991; 36: 1735–40PubMed
63.
Daneshmend TK, Hendrickse M, Salzmann M, et al. Does systemic absorption of 5-aminosalicylic acid from olsalazine (Dipentum®) and mesalazine (Asacol® and Pentasa®) differ significantly in ulcerative colitis? [abstract]. Gut 1994; 35 Suppl. 4: 233
64.
Staerk-Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271–6PubMed
65.
Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand 1994; 74: 399–402
66.
Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmaco-kinetics of drugs used in the treatment of gastrointestinal diseases (Part II). Clin Pharmacokinet 1990; 19: 94–125PubMed
67.
Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am Fam Physician 1998; 57: 57–68PubMed
68.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92: 204–11PubMed
69.
Ardizzone S, Molteni P, Bollani S, et al. Guidelines for the treatment of ulcerative colitis in remission. Eur J Gastroenterol Hepatol 1997; 9: 836–41PubMed
70.
Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for the treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 1188–97PubMed
71.
Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995; 30 Suppl. 8: 108–11
72.
Farup PG, Oddsson E, Hinterleitner T. Mesalamine 4 g prolonged release granules b.i.d. and q.i.d. versus tablets q.i.d. for mild/moderate ulcerative colitis [abstract]. Gastroenterology 1999; 116(2): A713
73.
Fockens P, Mulder CJJ, Tytgat GNJ, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 1025–30PubMed
74.
Mulder CJ, Tytgat GNJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis [see comments]. Gastroenterology 1988; 95: 1449–53PubMed
75.
Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995; 40: 296–304PubMed
76.
Hanauer SB, Meyers S. Management of Crohn’s disease in adults. Am J Gastroenterol 1997; 92(4): 559–66PubMed
77.
Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn’s disease [letter]. Gastroenterology 1994; 107: 632–3PubMed
78.
Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group [see comments]. Gastroenterology 1993; 104: 1293–301
79.
Hanauer SB, Krawitt EL, Robinson M, et al. Long-term management of Crohn’s disease with mesalamine capsules (Pentasa®). Am J Gastroenterol 1993; 88: 1343–51PubMed
80.
Colombel J-F, Lémann M, Cassagnou M, et al. Acontrolled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674–8PubMed
81.
Thomsen OØ, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. N Engl J Med 1998; 339: 370–4PubMed
82.
Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987; 22: 877–83
83.
Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion 1990; 45: 88–92PubMed
84.
Gendre J-P, Mary J-Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohns disease: a multicenter placebo-controlled study [in French]. Ann Gastroenterol Hepatol 1993; 29: 251–6
85.
Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn’s disease. Dig Dis Sci 1992; 37: 29–32PubMed
86.
Sutherland LR, Martin F, Bailey RJ, et al. 5-Aminosalicylic acid (Pentasa) in the maintenance of remission of Crohn’s disease [abstract]. Gastroenterology 1995; 108 Suppl.: 924
87.
Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopie recurrence after intestinal resection for Crohn’s disease. Italian Cooperative Study Group. Gastroenterology 1995; 108: 345–9
88.
Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 2000; 118: 264–73PubMed
89.
Bondesen S, Danish 5-ASA-group. Mesalazine (Pentasa) as prophylaxis in Crohn’s disease. A multicenter, controlled trial [abstract]. Scand J Gastroenterol 1991; 26 Suppl. 183: 68
90.
Modigliani R, Colombel J-F, Dupas J-L, et al. Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996; 110: 688–93PubMed
91.
Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn’s disease. J Pediatr Gastroenterol Nutr 1993; 17: 186–92PubMed
92.
Robinson M, Hanauer S, Hoop R, et al. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 27–34PubMed
93.
Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn’s disease. Dig Dis Sci 1995; 40: 931–5PubMed
94.
Zbrozek A, Hoop R, Robinson M, et al. Test of an instrument to measure function-related quality of life in patients with ulcerative colitis. Pharmacoeconomics 1993; 4(1): 31–9PubMed
95.
Kotanagi H, Ito M, Koyama K, et al. Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn’s disease. J Gastroenterol 1998; 33: 571–4PubMed
96.
Netzer P. Diffuse alopecia as side effect of mesalazine therapy in Crohn’s disease [in German]. Schweiz Med Wochenschr 1995; 125: 2438–42PubMed
97.
Declerck D, Wallaert B, Demarcq-Delerue G, et al. Diffuse interstitial pneumonia linked to 5-aminosalicylate [in French]. Rev Mal Respir 1994; 11: 292–3PubMed
98.
Janowski M, Laglenne S, Beaufils F. Hypersensitivity pneumopathy during treatment with mesalazine (Pentasa®). The value of bronchoalveolar lavage [in French]. Rev Med Interne 1992; 13: 545
99.
Besseau M, Delchier JC, Blazquez M, et al. Acute pancreatitis induced by mesalazine (Pentasa) [in French]. Gastroenterol Clin Biol 1991; 15(2): 174–5
100.
Gron I, Winther A. Exanthema in two patients with ulcerative colitis treated with Pentasa [in Danish]. Ugeskr Laeger 1988; 150: 32PubMed
101.
Kapur KC, Williams GT, Allison MC. Mesalazine induced exacerbation of ulcerative colitis. Gut 1995; 37: 838–9PubMed
102.
Marteau P, Nelet F, Lu LM, et al. Adverse events in patients treated with 5-aminosalicylic acid: 1993–1994 pharmaco-vigilance report for Pentasa in France. Aliment Pharmacol Ther 1996; 10: 949–56PubMed
103.
Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12: 1101–8PubMed
104.
Tennenbaum R, Marteau P, Elefant E, et al. Pregnancy outcome in inflammatory bowel disease [in French]. Gastroenterol Clin Biol 1998; 23(5): 464–9
105.
Pardi DS, Tremaine WJ, Sandborn WJ, et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93: 504–14PubMed
106.
Corrigan G, Stevens PE. Interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14(1): 1–6PubMed
107.
World MJ, Stevens PE, Ashton MA, et al. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11: 614–21PubMed
108.
Howard G, Lynn KL. Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring. Aust N Z J Med 1998; 28: 346PubMed
109.
Brouillard M, Gheerbrant JD, Gheysens Y, et al. Interstitial nephritis and mesalazine: three new cases [in French]. Gastroenterol Clin Biol 1998; 22: 724–6PubMed
110.
Be Broe ME, Stolear JC, Nouwen EJ, et al. 5-aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol Dial Transplant 1997; 12: 1839–41PubMed
111.
Colombel J-F, Brabant G, Gubler M-C, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? [letter]. Lancet 1994; 344: 620–1PubMed
112.
Mulder CJ, Tytgat GN, Dekker W, et al. Pentasa in lieu of sulfasalazine [letter]. Ann Intern Med 1988; 108: 911–2PubMed
113.
Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22(6): 452–5PubMed
114.
Steeno OP. Side-effects of salazopyrin on male fertility. Eur J Obstet Gynecol Reprod Biol 1984; 18(5–6): 361–4PubMed
115.
Kjaergaard N, Christensen LA, Lauritsen JG, et al. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scand J Gastroenterol 1989; 24(7): 891–6PubMed
116.
Zelissen PM, van-Hattum J, Poen H, et al. Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones. Scand J Gastroenterol 1988; 23: 1100–4PubMed
117.
Roberts Pharmaceuticals. Pentasa prescribing information. Eatontown, New Jersey, USA, 1998
118.
Pentasa data sheet. Ferring Pharmaceuticals. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. London: DataPharm Publications Ltd, 1999: 437–8
119.
Russel MGVM, Stockbrügger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417–27PubMed
120.
Harting JW. New developments in the pharmacotherapy of inflammatory bowel disease. Pharm Weekbl Sci 1992; 14: 275–86PubMed
121.
Glickman RM. Inflammatory bowel disease: ulcerative colitis and Crohn’s disease. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 14th ed. v. 2. New York: McGraw-Hill, 1998: 1633–45
122.
Ardizzone S, Bianchi PG. A practical guide to the management of distal ulcerative colitis. Drugs 1998; 55: 519–42PubMed
123.
Brynskov J, Rasmussen SN. Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 1996; 216: 175–80PubMed
124.
Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 1984; 101(3): 377–86PubMed
125.
Singleton JW, Law DH, Kelley Jr ML, et al. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 44 (4 Pt 2): 870–82
126.
Camilla C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465–73
127.
Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99(4): 956–63PubMed
128.
Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33(3): 1150–1
Metadata
Title
Prolonged-Release Mesalazine
A Review of its Therapeutic Potential in Ulcerative Colitis and Crohn’s Disease
Authors
Delyth Clemett
Anthony Markham
Publication date
01-04-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue 4/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200059040-00016

Other articles of this Issue 4/2000

Drugs 4/2000 Go to the issue

Review Article

A Risk-Benefit Assessment of Pharmacological and Nonpharmacological Treatments for Nausea and Vomiting of Pregnancy

Adis Drug Evaluation

Zolpidem

Adis New Drug Profile

Linezolid

Adis New Drug Profile

Linezolid

Adis Drug Evaluation

Celecoxib

Adis Drug Evaluation

Bupropion